[144] Cellebrite DI Ltd. SEC Filing

Rhea-AI Filing Summary

Cellebrite DI Ltd. (CLBT) filed a Form 144 reporting a proposed sale of 27,166 common shares with an aggregate market value of $481,313.61. The shares represent a small fraction of the 244,469,106 shares outstanding and are scheduled for sale on or about 09/19/2025 on NASDAQ. The shares were acquired as restricted stock from the issuer on 02/14/2025, 05/14/2025, and 08/14/2025, totaling 27,166 shares. The filing also discloses a sale during the past three months of 12,878 shares on 09/11/2025 for gross proceeds of $225,743.61. The document includes the required signer representation that no undisclosed material adverse information exists.

Positive

• Timely disclosure of proposed insider sale consistent with Rule 144 requirements
• Immaterial dilution: 27,166 shares represent approximately 0.011% of 244,469,106 shares outstanding
• Details provided: acquisition dates, broker name, prior sale and gross proceeds disclosed

Negative

• Insider selling: proposed sale and recent sale could be perceived negatively by some investors despite being small
• Filer identifiers missing in provided excerpt: CIK/CCC appear blank in the content supplied

Insights

Securities Analyst

TL;DR Insider plans to sell 27,166 restricted shares (~0.011% of shares outstanding); routine disclosure with negligible dilution.

The Form 144 describes a proposed sale of 27,166 common shares, acquired as restricted stock on three dates in 2025. Relative to the company's 244.5 million shares outstanding, the shares to be sold represent a de minimis amount, so the direct capitalization and voting dilution impact is immaterial. The filing follows standard Rule 144 procedures and includes a recent prior sale of 12,878 shares for $225,743.61. For investors, this is a transparency event rather than a company-operational signal.

Compliance / Risk Analyst

TL;DR Filing meets regulatory disclosure requirements; no disclosed material nonpublic information and routine 144 mechanics are followed.

The notice contains required disclosures about acquisition dates, nature of acquisition (restricted stock), and broker details (Morgan Stanley Smith Barney LLC). The filer attests there is no undisclosed material adverse information. No regulatory red flags appear in the form itself: acquisition and sale dates, amounts, and gross proceeds are provided. Absence of a listed filer CIK/CCC in the provided content is noted but may reflect omitted fields in this excerpt.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	27166	481313.61	244469106	09/19/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/14/2025	Restricted Stock	Issuer			9346	08/14/2025	Not Applicable
Common	02/14/2025	Restricted Stock	Issuer			8474	02/14/2025	Not Applicable
Common	05/14/2025	Restricted Stock	Issuer			9346	05/14/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
DANA GERNER 94 Shlomo Shmelzer Road Petah Tikva L3 4970602	Common	09/11/2025	12878	225743.61

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Cellebrite's (CLBT) Form 144 report?

The Form 144 reports a proposed sale of 27,166 common shares valued at $481,313.61, scheduled around 09/19/2025, on NASDAQ.

How many shares outstanding does the filing cite for CLBT?

The filing lists 244,469,106 shares outstanding.

When and how were the shares to be sold acquired?

All 27,166 shares were acquired as restricted stock from the issuer on 02/14/2025, 05/14/2025, and 08/14/2025.

Was there any recent sale by the same person?

Yes. The filing discloses a sale of 12,878 shares on 09/11/2025 for gross proceeds of $225,743.61 by Dana Gerner.

Which broker is handling the proposed sale?

The broker named is Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, NY.